



FOR IMMEDIATE RELEASE

August 15, 2019

Contact: Jacqueline Clark, [jacqueline@sqcomms.com](mailto:jacqueline@sqcomms.com)

Charlie Patterson, [charlie@sqcomms.com](mailto:charlie@sqcomms.com)

**George Hodgin, CEO of Biopharmaceutical Research Company: Congress Should Urgently Take Up Expansion of Cannabis Research In the Name of Veterans Health**

**MONTEREY, CA** - In the last eight months, there has been a flurry of legislative activity aimed at reducing barriers for marijuana research, as well as increasing access to marijuana treatment for our nation's veterans:

- Representative Matt Gaetz (R-FL-1) introduced the [Medical Cannabis Research Act](#) in January of 2019.
- Senator Ron Wyden (D-OR) and Representative Blumenauer (D-OR-3) introduced the [Responsibility Address the Marijuana Policy Gap Act](#) in February 2019.
- Senators Dianne Feinstein (D-CA), Chuck Grassley (R-IA) and Brian Schatz (D-HI) introduced the [Cannabidiol and Marijuana Research Expansion Act](#) in June of 2019.
- Representative Earl Blumenauer (D-OR-3) and Andy Harris (R-MD-1) introduced the [Medical Marijuana Research Act](#) in July of 2019.
- Representative Seth Moulton (D-MA-6) introduced the [VA Survey of Cannabis Use Act](#) in May of 2019.

The above pieces of legislation would remove barriers to research for marijuana-derived medications and CBD oils to pave the way for innovative new medications and treatments. George Hodgin, a former Navy SEAL and founder and CEO of Biopharmaceutical Research Company (BRC), issued the following statement supporting the legislation and calling for the urgent need for more research:

“At this point, we know that there is promise in cannabis and cannabidiol products for treating children, veterans and thousands of other Americans suffering from a wide range of illnesses and injuries. But research is so limited, that all we really know now is that there is promise. It is a responsibility of government to aid in the health of its citizens, and we have so many who could be helped by uncovering new treatments derived from cannabis.

“When Congress returns from recess, I urge them to do the right thing and take action to expand access to marijuana for research purposes as soon as possible so that, as a nation, we can truly lead on cannabis-based medicine and find out how much potential this plant has for healthcare. On behalf of those of all of us fighting for cannabis research rights, I thank Senator Feinstein, Senator Schatz and Senator Grassley, as well as Congressman Gaetz, Blumenauer, Harris and Moulton for continuing to lead on this issue.”

*George Hodgin is a graduate of the Stanford Graduate School of Business, a former Navy SEAL and the CEO of Biopharmaceutical Research Company near Monterey, CA. To learn more about BRC's work, visit <https://www.biopharmaresearchco.com/>.*

**About Biopharmaceutical Research Company**

BRC currently holds a DEA Registration and is working with the DEA for approval to manufacture clean, consistent and compliant cannabis for federally approved researchers around the world.

###